SentaVenir is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of: WHO Functional Class (FC) II to III, including use in combination treatment with tadalafil. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.